Cargando…

Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism

The intestinal capillary pathway is the most common way to absorb oral drugs, but for drugs with poor solubility and permeability and high first-pass metabolism, this pathway is very inefficient. Although intestinal lymphatic transport of lipophilic drugs or prodrugs is a promising strategy to impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinran, Zhang, Cai, Han, Ning, Luo, Juyuan, Zhang, Shuofeng, Wang, Chunguo, Jia, Zhanhong, Du, Shouying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330727/
https://www.ncbi.nlm.nih.gov/pubmed/34338567
http://dx.doi.org/10.1080/10717544.2021.1960928
_version_ 1783732779557584896
author Wang, Xinran
Zhang, Cai
Han, Ning
Luo, Juyuan
Zhang, Shuofeng
Wang, Chunguo
Jia, Zhanhong
Du, Shouying
author_facet Wang, Xinran
Zhang, Cai
Han, Ning
Luo, Juyuan
Zhang, Shuofeng
Wang, Chunguo
Jia, Zhanhong
Du, Shouying
author_sort Wang, Xinran
collection PubMed
description The intestinal capillary pathway is the most common way to absorb oral drugs, but for drugs with poor solubility and permeability and high first-pass metabolism, this pathway is very inefficient. Although intestinal lymphatic transport of lipophilic drugs or prodrugs is a promising strategy to improve the oral delivery efficiency of these drugs. The prodrug strategy for modifying compounds with Log P > 5 to promote intestinal lymphatic transport is a common approach. However, transport of poor liposoluble compounds (Log P < 0) through intestinal lymph has not been reported. Herein, triglyceride-mimetic prodrugs of scutellarin were designed and synthesized to promote intestinal lymphatic transport and increase oral bioavailability. Lymphatic transport and pharmacokinetic experiments showed that two prodrugs did promote intestinal lymphatic transport of scutellarin and the relative oral bioavailability was 2.24- and 2.45-fold of scutellarin, respectively. In summary, triglyceride-mimetic prodrugs strategy was used for the first time to study intestinal lymphatic transport of scutellarin with Log P < 0, which could further broaden the application range of drugs to improve oral bioavailability with the assistance of intestinal lymphatic transport.
format Online
Article
Text
id pubmed-8330727
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-83307272021-08-09 Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism Wang, Xinran Zhang, Cai Han, Ning Luo, Juyuan Zhang, Shuofeng Wang, Chunguo Jia, Zhanhong Du, Shouying Drug Deliv Research Article The intestinal capillary pathway is the most common way to absorb oral drugs, but for drugs with poor solubility and permeability and high first-pass metabolism, this pathway is very inefficient. Although intestinal lymphatic transport of lipophilic drugs or prodrugs is a promising strategy to improve the oral delivery efficiency of these drugs. The prodrug strategy for modifying compounds with Log P > 5 to promote intestinal lymphatic transport is a common approach. However, transport of poor liposoluble compounds (Log P < 0) through intestinal lymph has not been reported. Herein, triglyceride-mimetic prodrugs of scutellarin were designed and synthesized to promote intestinal lymphatic transport and increase oral bioavailability. Lymphatic transport and pharmacokinetic experiments showed that two prodrugs did promote intestinal lymphatic transport of scutellarin and the relative oral bioavailability was 2.24- and 2.45-fold of scutellarin, respectively. In summary, triglyceride-mimetic prodrugs strategy was used for the first time to study intestinal lymphatic transport of scutellarin with Log P < 0, which could further broaden the application range of drugs to improve oral bioavailability with the assistance of intestinal lymphatic transport. Taylor & Francis 2021-08-02 /pmc/articles/PMC8330727/ /pubmed/34338567 http://dx.doi.org/10.1080/10717544.2021.1960928 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Xinran
Zhang, Cai
Han, Ning
Luo, Juyuan
Zhang, Shuofeng
Wang, Chunguo
Jia, Zhanhong
Du, Shouying
Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
title Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
title_full Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
title_fullStr Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
title_full_unstemmed Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
title_short Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
title_sort triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330727/
https://www.ncbi.nlm.nih.gov/pubmed/34338567
http://dx.doi.org/10.1080/10717544.2021.1960928
work_keys_str_mv AT wangxinran triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism
AT zhangcai triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism
AT hanning triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism
AT luojuyuan triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism
AT zhangshuofeng triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism
AT wangchunguo triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism
AT jiazhanhong triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism
AT dushouying triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism